On October 28, 2021, The Galien Foundation honored excellence in the pharmaceutical, biotechnology, medical device, and digital health industry for research, development, and innovation at its 15th Annual Prix Galien Awards Gala at the American Museum of Natural History in New York City. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize for the life sciences industry.
Six world-leading biopharma companies responsible for development of COVID-19 vaccines and therapeutics jointly received the 2021 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. The Galien Foundation’s Awards Ceremony brought together competitors under one roof to honor their response to the pandemic by bringing safe, effective treatments to vulnerable patients in record time.
Senior leaders accepted the award from COVID-19 vaccine makers Pfizer/BioNTech SE, Moderna Inc., AstraZeneca PLC, and Johnson & Johnson, as well as top executives representing Regeneron Pharmaceuticals, which received Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV (casirivimab and imdevimab), and Eli Lilly & Company, which received EUA for bamlanivimab.
This historic ceremony was followed by the annual Galien Awards Ceremony. The winners of this year’s awards were Alcon, AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL) for “Best Medical Technology”; Global Blood Therapeutics, Inc. (GBT), Oxbryta (voxelotor) tablets for “Best Biotechnology Product”; Huma, Huma Therapeutics’ Remote Patient Monitoring Platform for “Best Digital Health Solution”; and Novartis Pharmaceuticals Corporation, Entresto (sacubitril/valsartan) for “Best Pharmaceutical Agent.”
